Two claims about South Africa’s ability to manufacture and develop vaccines.

Source: South African president Cyril Ramaphosa (12 July 2020)


One correct, one mostly correct.

South Africa has a history of producing human vaccines, though since the early 2000s it has not manufactured vaccines start to finish, largely due to cost.

The country has the expertise to develop vaccines, though to date only one locally developed human vaccine has made it to the human-trial stage of testing.

Many clinical trials are run in the country, including one currently for a potential Covid-19 vaccine.

Researched by Sarah Wild

There is currently no vaccine for the novel coronavirus that has infected millions of people around the world. However, a number of groups working to develop a vaccine against the Covid-19-causing virus.

According to the World Health Organization, as of 21 July 2020 there were 24 candidate vaccines in clinical evaluation.

In an address on 12 July, South African president Cyril Ramaphosa said: “Our country has an established vaccine manufacturing capability and expertise in the development and trial of a range of vaccines.”

Was he right? We checked.


South Africa “has an established vaccine manufacturing capability”



Before 2001, South Africa produced a number of its own human vaccines, including vaccines for polio and smallpox. This was done through its State Vaccine Institute, the South African Institute of Medical Research and National Institute of Virology. However, production at these facilities was terminated between 1995 and 2001. This was in part because of the high cost required to bring the vaccines in line with global best practice.

South Africa’s Biovac Institute, formed in 2003, is a public-private entity responsible for the government’s human vaccine procurement. It sources and provides vaccines as part of the government’s expanded programme on immunisation. It currently supplies 25-million doses of vaccines annually.

But the institute does not manufacture human vaccines from start to finish. “Biovac is here for human vaccine manufacture … but right now, we are not manufacturing human vaccines,” the institute’s CEO, Dr Morena Makhoana, told Africa Check.

Making vaccines from scratch work in progress

In a joint emailed statement, Makhoana, Medical Research Council president Glenda Gray, and Glaudina Loots from the national department of science and innovation confirmed to Africa Check that South Africa has the capability to manufacture human vaccines.

“This is critical for our country to expand its vaccine capability,” they said.

“People have different definitions of ‘manufacture’,” Makhoana told Africa Check.

The steps to manufacturing a vaccine range from growing and isolating the antigen which causes an immune response, to filling the vaccine into sterile containers and ensuring quality control.

In the next two months, Biovac will begin producing Sanofi’s six-in-one Hexaxim vaccine, which protects against diseases such as diphtheria, tetanus, pertussis, hepatitis B and polio. It expects to produce Pfizer’s Prevnar 13, a pneumonia vaccine, next year. But the company will import the blended or formulated material and fill it locally under sterile conditions, Makhoana said.

“We’re yet to establish capability of raw material manufacture for the active pharmaceutical ingredient [which] is sometimes called the ‘drug substance’,” he said. “We can develop vaccines, but we have yet to establish the raw material manufacture. We’re working on it, but it’s still a few years [away].”

Could country manufacture Covid-19 vaccine?

There are many different ways to make a vaccine. An RNA vaccine uses the genetic fingerprints of the antigen, a DNA vaccine contains the DNA sequence which will ignite an immune response, an inactivated vaccine employs a dead virus or bacterium and a subunit vaccine uses a specific piece of the germ (such as a protein or its casing) to elicit an immune response. A live vaccine contains a weakened living pathogen.

Each of these vaccines requires specific technology to manufacture. “There are some vaccines we can’t manufacture,” said Makhoana, “because technologically they can’t fit with what we have. But some are, and we’re exploring those capabilities.”

He said Biovac could manufacture mRNA, DNA, protein-subunit and inactivated vaccines. It would, however, need to import the raw material to do so. It does not have the capability to manufacture a live vaccine.

Makhoana said they were closely monitoring the development of Covid-19 vaccine candidates. “We’re betting on most horses, rather than one or two.

South Africa has ability to develop some vaccines

Ramaphosa claimed that South Africa “has an established vaccine manufacturing capability”. The Biovac Institute, a public-private entity, procures and supplies vaccines for the government.

However, the institute is not currently manufacturing any vaccines. It does have the capability to manufacture some types of vaccines using imported raw materials. We rate the claim “mostly correct”.


South Africa has “expertise in the development and trial of a range of vaccines”



South Africa has a great deal of expertise in the development of vaccines, particularly in veterinary science.

But there is only one locally developed human vaccine that has made it to the human-trial stage in the country, said Prof Ed Rybicki. He is a vaccine biotechnologist and director of the Biopharming Research Unit at the University of Cape Town (UCT).

The vaccine, developed by a team mostly from UCT, aimed to protect people against a strain of HIV. Makhoana, Gray and Loots confirmed this.

Biovac, on the other hand, has developed technology to create bacterial vaccines.

“We have developed a technology package for the manufacture of Haemophilus influenzae type b (Hib) conjugate vaccine,” it says on its website. This bacterium is responsible for severe pneumonia and meningitis in children under five. “To date, this has been transferred to two international vaccine manufacturers.”

Biovac does not manufacture these vaccines locally, but had the expertise to develop them.